Auralis
Now in Private Beta

Clinical Protocol
Generation, Automated

Upload study documents. Get ICH M11 compliant clinical protocols in minutes — not months. Built for medical writers and clinical teams.

Regulatory Frameworks

FDAEMATGAMHRAPMDANMPA
app.auralis.solutions
Auralis
DashboardNew ProtocolSettings
Oncology Phase 2 ProtocolMar 5, 2026
DOCX
PDF

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of XYZ-101 in Patients with Advanced Non-Small Cell Lung Cancer

Protocol #: AUR-2026-0042  Version: 1.0  Sponsor: Acme Therapeutics

1.1Protocol Synopsis
Brief Title
Phase 2 Study of XYZ-101 in Advanced Non-Small Cell Lung Cancer
Indication
Advanced non-small cell lung cancer (NSCLC) and metastatic squamous cell carcinoma
Study Design
This randomized, double-blind, placebo-controlled Phase 2 study evaluates the efficacy and safety of XYZ-101 in combination with standard-of-care chemotherapy in patients with advanced NSCLC. Part A focuses on dose optimization using a 3+3 design, while Part B is a randomized expansion evaluating preliminary efficacy across two dosing cohorts.

Capabilities

AI-Powered Document Generation

Generate clinical study protocols, investigator brochures, and clinical study reports with advanced AI technology.

Global Regulatory Compliance

Built-in compliance for all jurisdictions including FDA, EMA, TGA, MHRA, KFDA, NMPA, and PMDA amongst other regulatory authorities.

All Clinical Trial Phases

Comprehensive support from Phase I through Phase IV, adapting documentation requirements for each study phase.

How It Works

01

Input Study Requirements

Upload study objectives, endpoints, population criteria, and regulatory requirements to our secure platform.

02

AI Document Generation

Advanced AI generates protocols, investigator brochures, and study reports tailored to your specific trial phase and jurisdiction.

03

Regulatory-Ready Documents

Receive compliant clinical documents formatted for submission to regulatory authorities worldwide.

Frequently Asked Questions

Auralis generates protocols following the ICH M11 (CeSHarP) 14-section template structure, which is accepted by FDA, EMA, TGA, MHRA, PMDA, NMPA, and KFDA. The output is designed to meet global regulatory expectations across all major jurisdictions.

Yes. Every section of the generated protocol is fully editable in our built-in viewer. You can modify text, update structured fields, and export the final version as DOCX or PDF. Medical writers retain full control over the output.

All uploaded documents are encrypted in transit and at rest. We use Supabase for secure storage with row-level security policies. Your study data is never used to train models and is only accessible within your account.

Auralis accepts PDF, DOCX, DOC, and TXT files. You can upload multiple documents per protocol — study synopses, investigator brochures, statistical analysis plans, or any supporting study documents.

Auralis uses a multi-agent architecture with state-of-the-art language models from Anthropic and OpenAI. Specialized agents handle different protocol sections, with built-in search tools for PubMed, clinical trial registries, and regulatory guidance.

A full 14-section ICH M11 protocol is typically generated in 3–8 minutes, depending on the complexity of the study and the volume of uploaded source documents.

Ready to Accelerate Your Clinical Development?

Join pharmaceutical companies streamlining their clinical documentation with AI-powered automation across all trial phases.

Auralis

Automating development of clinical study protocols, investigator brochures, and clinical study reports for drug developers across all trial phases and jurisdictions.

© 2026 Auralis. All rights reserved.